Highlights for June 2017

  1. Pfizer acquires AstraZeneca’s heartburn drug in India for $13.89 Millions.
  2. Thermo Fisher Scientific aproves acquisition of Patheon
  3. AstraZeneca offloads headache drug Zomig to Grünenthal to raise $300M cash.
  4. Merck KGaA, F-Star in bispecific biobucks bonanza deal.
  5. Innate Pharma and Novo Nordisk pen early I-O cancer drug deal.
  6. ImmunoGen gets $30M amid Sanofi ADC deal shake-up.
  7. Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug.
  8. Celgene bags option on NK cell-based blood cancer assets.
  9. Lilly pays $55M for rights to KeyBioscience’s diabetes assets.
  10. Clinigen makes 3 exclusive compassionate-use deals.
  11. ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.
  12. AMTZ Inks Pact With Common Scientific Facilities Service Providers

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.(https://www.linkedin.com/groups/4500189)